Medicare and Medicaid will cover the cost of infusion associated with Dendreon Corp’s prostate cancer vaccine Provenge, the company said on Monday. The ruling by the Centers for Medicare and Medicaid Services sent Dendreon shares up as much as 9 percent.
The Seattle-based company said that under the updated coverage policy, the costs associated with administering Provenge can now be billed separately.
Read the rest of this entry »